NeuroThera Labs, SciSparc Subsidiary, Closes CliniQuantum Acquisition Valued at $9.46M
SPRC has more than doubled off its 52-week low of $2.98 on light trading volume (0.2× avg).
Summary
NeuroThera Labs Inc., a majority-owned subsidiary of SciSparc Ltd., has finalized its acquisition of a 54.01% stake in CliniQuantum Ltd. The transaction involved NeuroThera Labs issuing 56.6 million common shares with a deemed value of approximately $9.46 million, along with potential earn-out payments of up to $2.5 million. This closing follows the definitive agreement announced in March and the conditional regulatory approvals received in late May. The acquisition is a significant strategic move for SciSparc's subsidiary, expanding its capabilities into quantum technology applications for clinical trial data analysis, and is material relative to SciSparc's current market capitalization.
At the time of this announcement, SPRC was trading at $9.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4M. The 52-week trading range was $2.98 to $80.10. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: TheNewswire.